FDA Head Urges Investigation Into Her Agency’s ‘Interactions’ With Drug Company

Fight Censorship, Share This Post!

The acting head of the Food and Drug Administration (FDA) urged for a government investigation into unusual contacts between members of her agency and the maker of a controversial new drug for Alzheimer’s disease Friday.

Dr. Janet Woodcock, acting commissioner of the FDA, tweeted that due to “ongoing interest and questions” she has asked the Office of the Inspector General, U.S. Department of Health and Human Services for an independent investigation into the “interactions between representatives of Biogen and FDA” during the approval process for Aduhelm, an Alzheimer’s drug.


Fight Censorship, Share This Post!

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.